Trial
NCT02766140
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborators
Shanghai Pulmonary Hospital, Shanghai, China
Condition
Non Squamous Non Small Cell Lung
Intervention
SHR1020 plus Docetaxel
Why stopped
difficulty in recruitment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-18